• Infection Control

  AstraZeneca vaccine efficacy for smaller dosage explained

  Posted by Unknown Member on 25 November 2020 at 6:16 pm

  <div>

  A seemingly strange phenomenon of a smaller dose of the Oxford-AstraZeneca Covid-19 vaccine being more effective than a bigger one is reportedly explained by it first being tested on a younger group.

  On Monday, the pharmacological company announced that its AZD1222 vaccine for Covid-19, which is based on a common cold virus that causes infection in chimpanzees, has an efficacy of 70 percent. The number is average for two slightly different tests. One involved people, who received half a dose of the vaccine, followed by a full dose a month later, while the larger second group took full doses for both shots.

  Counterintuitively, the first regimen showed 90 percent efficacy, compared to 62 percent for the second group of subjects.

  A larger dosage usually produces a stronger immune response, so the discrepancy made some experts wonder. Apparently, AstraZeneca omitted a key detail of their study that explains the results, Bloomberg reported on Tuesday citing Moncef Slaou, the head of the US Operation Warp Speed program.

  The half-dose variant was tested on people aged between 18 and 55, while the full-dose test included elderly people. Younger people tend to have stronger responses to some kinds of vaccines. AstraZeneca earlier stated their study has proven a strong response among the elderly. The difference in dosage was not by design but rather due to an error in the quantity of vaccine put into some vials, according to Slaou.

  The British-Swedish multinational is one of many vaccine producers racing to offer their products to nations worldwide. Many have published preliminary results of their studies, which indicate a better-than-expected efficacy, boosting public optimism about overcoming the Covid-19 pandemic. Publications of their full reports in peer-reviewed scientific journals are still in the pipeline, however.

  </div>

  Unknown Member replied 3 years, 10 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply